nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—HTR1B—attention deficit hyperactivity disorder	0.243	0.325	CbGaD
Ergotamine—ADRA2A—attention deficit hyperactivity disorder	0.215	0.288	CbGaD
Ergotamine—DRD2—attention deficit hyperactivity disorder	0.163	0.218	CbGaD
Ergotamine—HTR2A—attention deficit hyperactivity disorder	0.126	0.169	CbGaD
Ergotamine—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.00673	0.102	CbGeAlD
Ergotamine—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.00405	0.0612	CbGeAlD
Ergotamine—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00358	0.0541	CbGeAlD
Ergotamine—HTR1F—forebrain—attention deficit hyperactivity disorder	0.00254	0.0385	CbGeAlD
Ergotamine—HTR1E—forebrain—attention deficit hyperactivity disorder	0.0022	0.0333	CbGeAlD
Ergotamine—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.00215	0.0325	CbGeAlD
Ergotamine—HTR1F—nervous system—attention deficit hyperactivity disorder	0.00138	0.0209	CbGeAlD
Ergotamine—ADRA1D—forebrain—attention deficit hyperactivity disorder	0.00135	0.0204	CbGeAlD
Ergotamine—HTR1F—central nervous system—attention deficit hyperactivity disorder	0.00133	0.0201	CbGeAlD
Ergotamine—HTR1E—nervous system—attention deficit hyperactivity disorder	0.0012	0.0181	CbGeAlD
Ergotamine—HTR1E—central nervous system—attention deficit hyperactivity disorder	0.00115	0.0174	CbGeAlD
Ergotamine—HTR1F—brain—attention deficit hyperactivity disorder	0.00105	0.016	CbGeAlD
Ergotamine—HTR1B—forebrain—attention deficit hyperactivity disorder	0.00104	0.0158	CbGeAlD
Ergotamine—HTR1D—forebrain—attention deficit hyperactivity disorder	0.00101	0.0153	CbGeAlD
Ergotamine—HTR2C—forebrain—attention deficit hyperactivity disorder	0.000999	0.0151	CbGeAlD
Ergotamine—HTR2B—forebrain—attention deficit hyperactivity disorder	0.000938	0.0142	CbGeAlD
Ergotamine—HTR1E—brain—attention deficit hyperactivity disorder	0.000914	0.0138	CbGeAlD
Ergotamine—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.000881	0.0133	CbGeAlD
Ergotamine—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.000853	0.0129	CbGeAlD
Ergotamine—HTR1A—forebrain—attention deficit hyperactivity disorder	0.000841	0.0127	CbGeAlD
Ergotamine—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.000834	0.0126	CbGeAlD
Ergotamine—HTR2B—cardiovascular system—attention deficit hyperactivity disorder	0.000793	0.012	CbGeAlD
Ergotamine—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.000775	0.0117	CbGeAlD
Ergotamine—DRD2—forebrain—attention deficit hyperactivity disorder	0.00076	0.0115	CbGeAlD
Ergotamine—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.000749	0.0113	CbGeAlD
Ergotamine—ADRA1D—nervous system—attention deficit hyperactivity disorder	0.000732	0.0111	CbGeAlD
Ergotamine—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.000721	0.0109	CbGeAlD
Ergotamine—HTR1A—cardiovascular system—attention deficit hyperactivity disorder	0.000711	0.0108	CbGeAlD
Ergotamine—ADRA1D—central nervous system—attention deficit hyperactivity disorder	0.000705	0.0107	CbGeAlD
Ergotamine—HTR1B—midbrain—attention deficit hyperactivity disorder	0.000688	0.0104	CbGeAlD
Ergotamine—HTR1D—midbrain—attention deficit hyperactivity disorder	0.000666	0.0101	CbGeAlD
Ergotamine—Ergoloid mesylate—DRD1—attention deficit hyperactivity disorder	0.000659	0.0741	CrCbGaD
Ergotamine—HTR2C—midbrain—attention deficit hyperactivity disorder	0.000659	0.00998	CbGeAlD
Ergotamine—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000655	0.00992	CbGeAlD
Ergotamine—Lisuride—DRD5—attention deficit hyperactivity disorder	0.000619	0.0696	CrCbGaD
Ergotamine—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000589	0.00892	CbGeAlD
Ergotamine—Lisuride—ADRA2C—attention deficit hyperactivity disorder	0.000584	0.0656	CrCbGaD
Ergotamine—Bromocriptine—DRD5—attention deficit hyperactivity disorder	0.000573	0.0644	CrCbGaD
Ergotamine—ADRA1B—brain—attention deficit hyperactivity disorder	0.000572	0.00866	CbGeAlD
Ergotamine—HTR1B—nervous system—attention deficit hyperactivity disorder	0.000565	0.00856	CbGeAlD
Ergotamine—ADRA1D—brain—attention deficit hyperactivity disorder	0.00056	0.00847	CbGeAlD
Ergotamine—HTR1A—midbrain—attention deficit hyperactivity disorder	0.000555	0.0084	CbGeAlD
Ergotamine—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000547	0.00829	CbGeAlD
Ergotamine—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000544	0.00824	CbGeAlD
Ergotamine—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000542	0.00821	CbGeAlD
Ergotamine—Bromocriptine—ADRA2C—attention deficit hyperactivity disorder	0.000541	0.0608	CrCbGaD
Ergotamine—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000527	0.00798	CbGeAlD
Ergotamine—Dihydroergotamine—HTR1B—attention deficit hyperactivity disorder	0.000524	0.0589	CrCbGaD
Ergotamine—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.000522	0.0079	CbGeAlD
Ergotamine—HTR2B—nervous system—attention deficit hyperactivity disorder	0.000509	0.00771	CbGeAlD
Ergotamine—DRD2—midbrain—attention deficit hyperactivity disorder	0.000502	0.00759	CbGeAlD
Ergotamine—HTR2A—forebrain—attention deficit hyperactivity disorder	0.000501	0.00758	CbGeAlD
Ergotamine—HTR2B—central nervous system—attention deficit hyperactivity disorder	0.00049	0.00742	CbGeAlD
Ergotamine—Ergoloid mesylate—DRD2—attention deficit hyperactivity disorder	0.000465	0.0523	CrCbGaD
Ergotamine—Dihydroergotamine—ADRA2A—attention deficit hyperactivity disorder	0.000464	0.0522	CrCbGaD
Ergotamine—HTR1A—nervous system—attention deficit hyperactivity disorder	0.000456	0.00691	CbGeAlD
Ergotamine—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.000452	0.00685	CbGeAlD
Ergotamine—HTR1A—central nervous system—attention deficit hyperactivity disorder	0.000439	0.00665	CbGeAlD
Ergotamine—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.000436	0.00659	CbGeAlD
Ergotamine—HTR1B—brain—attention deficit hyperactivity disorder	0.000432	0.00654	CbGeAlD
Ergotamine—HTR1A—cerebellum—attention deficit hyperactivity disorder	0.000429	0.0065	CbGeAlD
Ergotamine—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000424	0.00641	CbGeAlD
Ergotamine—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000421	0.00637	CbGeAlD
Ergotamine—HTR1D—brain—attention deficit hyperactivity disorder	0.000418	0.00633	CbGeAlD
Ergotamine—HTR2C—brain—attention deficit hyperactivity disorder	0.000414	0.00627	CbGeAlD
Ergotamine—DRD2—nervous system—attention deficit hyperactivity disorder	0.000412	0.00624	CbGeAlD
Ergotamine—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000405	0.00613	CbGeAlD
Ergotamine—Methylergometrine—DRD1—attention deficit hyperactivity disorder	0.0004	0.0449	CrCbGaD
Ergotamine—DRD2—central nervous system—attention deficit hyperactivity disorder	0.000397	0.00601	CbGeAlD
Ergotamine—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000396	0.00599	CbGeAlD
Ergotamine—HTR2B—brain—attention deficit hyperactivity disorder	0.000389	0.00589	CbGeAlD
Ergotamine—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000389	0.00589	CbGeAlD
Ergotamine—DRD2—cerebellum—attention deficit hyperactivity disorder	0.000388	0.00587	CbGeAlD
Ergotamine—Methysergide—HTR1B—attention deficit hyperactivity disorder	0.00035	0.0393	CrCbGaD
Ergotamine—HTR1A—brain—attention deficit hyperactivity disorder	0.000349	0.00528	CbGeAlD
Ergotamine—SLC6A2—brain—attention deficit hyperactivity disorder	0.000346	0.00524	CbGeAlD
Ergotamine—HTR2A—midbrain—attention deficit hyperactivity disorder	0.000331	0.00501	CbGeAlD
Ergotamine—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000328	0.00497	CbGeAlD
Ergotamine—ADRA1A—brain—attention deficit hyperactivity disorder	0.000322	0.00487	CbGeAlD
Ergotamine—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.00032	0.00484	CbGeAlD
Ergotamine—Lisuride—DRD4—attention deficit hyperactivity disorder	0.000317	0.0356	CrCbGaD
Ergotamine—DRD2—brain—attention deficit hyperactivity disorder	0.000315	0.00477	CbGeAlD
Ergotamine—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000308	0.00466	CbGeAlD
Ergotamine—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000301	0.00456	CbGeAlD
Ergotamine—Bromocriptine—DRD4—attention deficit hyperactivity disorder	0.000293	0.033	CrCbGaD
Ergotamine—Lisuride—HTR1B—attention deficit hyperactivity disorder	0.000281	0.0316	CrCbGaD
Ergotamine—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000278	0.0042	CbGeAlD
Ergotamine—Lisuride—DRD3—attention deficit hyperactivity disorder	0.000273	0.0307	CrCbGaD
Ergotamine—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000272	0.00412	CbGeAlD
Ergotamine—Lisuride—DRD1—attention deficit hyperactivity disorder	0.000268	0.0301	CrCbGaD
Ergotamine—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000262	0.00396	CbGeAlD
Ergotamine—Bromocriptine—HTR1B—attention deficit hyperactivity disorder	0.000261	0.0293	CrCbGaD
Ergotamine—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000256	0.00387	CbGeAlD
Ergotamine—Bromocriptine—DRD3—attention deficit hyperactivity disorder	0.000253	0.0284	CrCbGaD
Ergotamine—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000252	0.00381	CbGeAlD
Ergotamine—Lisuride—ADRA2A—attention deficit hyperactivity disorder	0.000249	0.028	CrCbGaD
Ergotamine—Bromocriptine—DRD1—attention deficit hyperactivity disorder	0.000248	0.0279	CrCbGaD
Ergotamine—ADRA2A—brain—attention deficit hyperactivity disorder	0.000244	0.0037	CbGeAlD
Ergotamine—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000242	0.00367	CbGeAlD
Ergotamine—Bromocriptine—ADRA2A—attention deficit hyperactivity disorder	0.000231	0.0259	CrCbGaD
Ergotamine—Methylergometrine—HTR2A—attention deficit hyperactivity disorder	0.000218	0.0245	CrCbGaD
Ergotamine—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000217	0.00328	CbGeAlD
Ergotamine—HTR2A—brain—attention deficit hyperactivity disorder	0.000208	0.00315	CbGeAlD
Ergotamine—Lisuride—DRD2—attention deficit hyperactivity disorder	0.000189	0.0212	CrCbGaD
Ergotamine—Methysergide—HTR2A—attention deficit hyperactivity disorder	0.000182	0.0204	CrCbGaD
Ergotamine—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000178	0.0027	CbGeAlD
Ergotamine—Bromocriptine—DRD2—attention deficit hyperactivity disorder	0.000175	0.0197	CrCbGaD
Ergotamine—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000172	0.0026	CbGeAlD
Ergotamine—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000168	0.00254	CbGeAlD
Ergotamine—Lisuride—HTR2A—attention deficit hyperactivity disorder	0.000146	0.0164	CrCbGaD
Ergotamine—ABCB1—brain—attention deficit hyperactivity disorder	0.000136	0.00206	CbGeAlD
Ergotamine—Bromocriptine—HTR2A—attention deficit hyperactivity disorder	0.000135	0.0152	CrCbGaD
Ergotamine—ADRA2B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.77e-05	9.91e-05	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.77e-05	9.91e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.76e-05	9.85e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	1.76e-05	9.85e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.75e-05	9.8e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.75e-05	9.79e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.74e-05	9.74e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	1.73e-05	9.72e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	1.73e-05	9.72e-05	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.73e-05	9.7e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.73e-05	9.69e-05	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.72e-05	9.65e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.71e-05	9.59e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.71e-05	9.57e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.71e-05	9.57e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	1.71e-05	9.56e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.7e-05	9.52e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	1.69e-05	9.49e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.69e-05	9.45e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	1.69e-05	9.45e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	1.69e-05	9.45e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.68e-05	9.41e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.68e-05	9.4e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	1.67e-05	9.37e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	1.67e-05	9.36e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	1.67e-05	9.34e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	1.66e-05	9.3e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.65e-05	9.27e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.65e-05	9.26e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.65e-05	9.26e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	1.65e-05	9.25e-05	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.65e-05	9.23e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	1.63e-05	9.15e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.63e-05	9.14e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.63e-05	9.12e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.63e-05	9.11e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.63e-05	9.11e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	1.62e-05	9.1e-05	CbGpPWpGaD
Ergotamine—HTR1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.62e-05	9.1e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	1.62e-05	9.1e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.62e-05	9.08e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.62e-05	9.07e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.61e-05	9.01e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.61e-05	9e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.6e-05	8.99e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.59e-05	8.93e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.59e-05	8.92e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	1.59e-05	8.92e-05	CbGpPWpGaD
Ergotamine—HTR1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.59e-05	8.92e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.57e-05	8.83e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.57e-05	8.81e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.57e-05	8.81e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.56e-05	8.76e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.56e-05	8.75e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	1.55e-05	8.7e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.55e-05	8.69e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.53e-05	8.56e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.53e-05	8.55e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.52e-05	8.5e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	1.52e-05	8.5e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	1.51e-05	8.46e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.5e-05	8.43e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.5e-05	8.41e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.5e-05	8.4e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.5e-05	8.39e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.5e-05	8.39e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.49e-05	8.38e-05	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.49e-05	8.37e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.48e-05	8.3e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.48e-05	8.29e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.48e-05	8.27e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.48e-05	8.27e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.47e-05	8.24e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.46e-05	8.2e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.46e-05	8.18e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.46e-05	8.17e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.45e-05	8.13e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.44e-05	8.1e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.44e-05	8.1e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.43e-05	8e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.42e-05	7.96e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.41e-05	7.9e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.41e-05	7.88e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.39e-05	7.8e-05	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.39e-05	7.79e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.38e-05	7.71e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.37e-05	7.65e-05	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.36e-05	7.64e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.36e-05	7.62e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.36e-05	7.61e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.36e-05	7.61e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.35e-05	7.58e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.35e-05	7.57e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.35e-05	7.55e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.34e-05	7.49e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.33e-05	7.45e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.33e-05	7.43e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.32e-05	7.42e-05	CbGpPWpGaD
Ergotamine—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	1.31e-05	7.35e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.31e-05	7.33e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.31e-05	7.33e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.31e-05	7.32e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.3e-05	7.31e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.3e-05	7.27e-05	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.29e-05	7.2e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.27e-05	7.09e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.26e-05	7.08e-05	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.26e-05	7.04e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.25e-05	7e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	1.25e-05	6.98e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.25e-05	6.98e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.24e-05	6.97e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.24e-05	6.97e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.24e-05	6.96e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.23e-05	6.92e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.23e-05	6.89e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	1.23e-05	6.87e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.22e-05	6.83e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.22e-05	6.81e-05	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.21e-05	6.79e-05	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.21e-05	6.76e-05	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	1.2e-05	6.75e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.18e-05	6.62e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.18e-05	6.6e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.16e-05	6.49e-05	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.15e-05	6.47e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.14e-05	6.42e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.14e-05	6.41e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.14e-05	6.41e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.14e-05	6.39e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.14e-05	6.39e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.14e-05	6.39e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.13e-05	6.36e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.13e-05	6.31e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.1e-05	6.18e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.1e-05	6.17e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.1e-05	6.15e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.09e-05	6.14e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.09e-05	6.08e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.06e-05	5.97e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.06e-05	5.96e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.06e-05	5.96e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.06e-05	5.94e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.05e-05	5.91e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	1.05e-05	5.9e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.05e-05	5.87e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.04e-05	5.86e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.03e-05	5.78e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.03e-05	5.75e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.02e-05	5.74e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.02e-05	5.74e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.02e-05	5.72e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.01e-05	5.66e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.01e-05	5.65e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1e-05	5.62e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1e-05	5.61e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	9.96e-06	5.58e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.96e-06	5.58e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.96e-06	5.58e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.91e-06	5.56e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.85e-06	5.52e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.77e-06	5.48e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	9.66e-06	5.41e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.64e-06	5.4e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9.61e-06	5.39e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.61e-06	5.38e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.52e-06	5.34e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.49e-06	5.32e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	9.31e-06	5.22e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.3e-06	5.21e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9.28e-06	5.2e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9.23e-06	5.17e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.15e-06	5.13e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.01e-06	5.05e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.96e-06	5.02e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.96e-06	5.02e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.87e-06	4.97e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.86e-06	4.96e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.84e-06	4.95e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.75e-06	4.9e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.71e-06	4.88e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.71e-06	4.88e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.68e-06	4.87e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.65e-06	4.85e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	8.61e-06	4.83e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.61e-06	4.83e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.61e-06	4.82e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.53e-06	4.78e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.53e-06	4.78e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	8.48e-06	4.75e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.43e-06	4.72e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.33e-06	4.67e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.07e-06	4.52e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.02e-06	4.49e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.02e-06	4.49e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	7.98e-06	4.47e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.88e-06	4.42e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.85e-06	4.4e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.83e-06	4.39e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.69e-06	4.31e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	7.55e-06	4.23e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	7.49e-06	4.2e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.46e-06	4.18e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.29e-06	4.09e-05	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.22e-06	4.05e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.89e-06	3.86e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	6.88e-06	3.85e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.88e-06	3.85e-05	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.81e-06	3.82e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	6.77e-06	3.79e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.73e-06	3.77e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.56e-06	3.67e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.5e-06	3.64e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.47e-06	3.62e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.29e-06	3.53e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.19e-06	3.47e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.71e-06	3.2e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.5e-06	3.08e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.5e-06	3.08e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	5.31e-06	2.97e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.31e-06	2.97e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.23e-06	2.93e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	5.22e-06	2.93e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	5.22e-06	2.93e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	5.18e-06	2.9e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.11e-06	2.86e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.85e-06	2.72e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.62e-06	2.59e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.52e-06	2.53e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.25e-06	2.38e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.24e-06	2.38e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	4.17e-06	2.34e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	4.14e-06	2.32e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.04e-06	2.26e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	4.01e-06	2.25e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.95e-06	2.21e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.57e-06	2e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.44e-06	1.93e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.43e-06	1.92e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.28e-06	1.84e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	3.24e-06	1.81e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	3.22e-06	1.8e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	3.19e-06	1.79e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.02e-06	1.69e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.97e-06	1.67e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.91e-06	1.63e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.71e-06	1.52e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	2.24e-06	1.25e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	1.79e-06	1e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	1.38e-06	7.73e-06	CbGpPWpGaD
